Bimat is applied as sterile ophthalmic drops, with the regimen confirmed by a healthcare professional before starting. It contains bimatoprost 0.01% w/v, a prostaglandin analogue used to lower raised…
Bimat is applied as sterile ophthalmic drops, with the regimen confirmed by a healthcare professional before starting. It contains bimatoprost 0.01% w/v, a prostaglandin analogue used to lower raised intraocular pressure in glaucoma and ocular hypertension.
Bimat is a sterile ophthalmic product containing bimatoprost 0.01% w/v. It belongs to the prostaglandin analogue class and is used to reduce elevated intraocular pressure.
Bimat contains bimatoprost 0.01% w/v in a sterile ophthalmic solution supplied in a bottle. Bimatoprost belongs to the prostaglandin analogue class and is used in eye care to reduce elevated intraocular pressure. The product is intended for application to the eye, not for oral use or application to the skin.
Raised intraocular pressure can damage the optic nerve gradually. Glaucoma may progress without pain or obvious early symptoms, so treatment aims to control pressure before further optic-nerve injury occurs. Bimatoprost is listed in regulatory ophthalmic information as a pressure-lowering treatment for conditions such as open-angle glaucoma and ocular hypertension [1].
Bimatoprost is a synthetic prostamide-related compound with effects on aqueous-humour drainage. Aqueous humour is the clear fluid produced inside the eye. When its production and drainage are unbalanced, intraocular pressure can rise.
The regimen for this chosen strength should be confirmed with a healthcare professional before starting.
The product is supplied as drops in a 3 ml bottle.
Bimatoprost may also affect eyelash follicles by prolonging the active growth phase of lashes. Published eyelash studies mainly evaluated specific cosmetic formulations and concentrations, so use for eyelash hypotrichosis requires a clinician-confirmed regimen rather than assuming that an eye-pressure dose is interchangeable with a lash-growth protocol.
In glaucoma or ocular hypertension, the treatment goal is a sustained reduction in intraocular pressure that helps protect the optic nerve. For eyelash hypotrichosis, research with bimatoprost-based treatment found progressive changes in lash length, darkness and fullness over several weeks.
NICE guidance recommends pressure monitoring as part of ongoing glaucoma management [2].
The regimen for Bimat should be confirmed with a healthcare professional before starting. The prescribed schedule depends on the condition being treated, the pressure target and whether another eye drop is already being used.
For ophthalmic use, the practical procedure is:
Bimat should be used at the same time each day when a once-daily schedule has been prescribed. Do not increase the frequency to speed up the response. More frequent use may reduce the pressure-lowering response and may increase local irritation.
When several eye medicines are prescribed, separate their applications by at least five minutes unless the prescribing clinician has provided another schedule. Eye ointments are generally applied after drops because an ointment layer can interfere with later drop penetration.
The bottle is for ophthalmic use only. It should not be swallowed, poured onto contact lenses or used by another person.
If a dose is forgotten, apply it when remembered unless the next scheduled dose is close. In that situation, skip the missed dose and continue at the normal time. Do not apply extra drops.
Bimat is not for you if you have had an allergic reaction to bimatoprost or any ingredient in the drops. You should speak to a clinician before use if you have eye inflammation, corneal problems, macular oedema, previous herpes infection of the cornea, cataract-surgery complications, or are pregnant or breastfeeding. Do not add another pressure-lowering prostaglandin drop or stop glaucoma treatment without medical direction.
The most frequent reactions are local and affect the eye or surrounding skin. Reported effects with bimatoprost ophthalmic products include:
Redness may be more noticeable during the first weeks. It can improve with continued treatment, though persistent or troublesome redness requires clinical review.
Bimatoprost may gradually increase brown pigmentation of the iris. This change can be permanent, especially in eyes with mixed iris colours. The change may develop slowly and may not be obvious at first. The prescribing clinician should document the baseline appearance of the iris when appropriate.
Skin darkening around the eyelids may improve after stopping treatment, while iris pigmentation may remain. Eyelash changes may include longer lashes, uneven growth or lashes touching the eye surface.
Rare but urgent problems include marked eye pain, a sudden change in vision, pronounced light sensitivity, severe swelling or symptoms suggesting an allergic reaction. These symptoms require prompt medical attention.
Bimatoprost lowers intraocular pressure by increasing the outflow of aqueous humour through the uveoscleral route. This gives fluid an additional pathway to leave the eye, reducing pressure inside the eye over time.
Bimatoprost also interacts with biological pathways involved in the hair-growth cycle. Eyelash follicles move through anagen, the active growth phase; catagen, a transitional phase; and telogen, a resting phase. Bimatoprost may increase the proportion of lashes in anagen and may make lashes appear longer, darker or thicker. The supporting clinical evidence concerns dedicated eyelash-treatment regimens, including bimatoprost 0.03%, rather than automatically confirming the same cosmetic result from Bimat 0.01% [5]. Changes in lash appearance should be discussed before treatment is continued for cosmetic reasons.
One missed dose is usually managed by returning to the regular schedule. Repeated missed doses are different because they may compromise pressure control. A simple daily routine, such as applying the drop at the same evening hygiene step, can reduce forgotten applications.
Bimatoprost, latanoprost and beta-blocker eye drops lower intraocular pressure through different pharmacological pathways. The choice depends on pressure control, eye history, heart and lung conditions, dosing preference and adverse effects.
| Treatment category | Main pressure-lowering pathway | Key clinical limitation |
|---|---|---|
| Bimatoprost | Increases uveoscleral aqueous-humour outflow | Redness, eyelid or iris pigmentation and lash changes may occur |
| Latanoprost | Increases uveoscleral aqueous-humour outflow through prostaglandin-related activity | Similar local effects can occur; response varies between patients |
| Beta-blocker eye drops | Reduces aqueous-humour production | May be unsuitable with asthma, slow heart rate or some cardiac conditions |
Bimatoprost and latanoprost are pharmacologically related, but they are not interchangeable without a prescribing decision. A person already using latanoprost should not add Bimat independently.
Beta-blocker drops can be useful for some patients but may have systemic effects after absorption through the tear duct. This is why a history of asthma, chronic obstructive pulmonary disease, bradycardia or heart block matters when selecting treatment.
The American Academy of Ophthalmology identifies prostaglandin-type therapy as an important option for primary open-angle glaucoma, while treatment remains individualised according to the target pressure and risk of progression [4].
In clinical practice, doctors usually judge Bimat by measured intraocular pressure, optic-nerve findings and visual-field results rather than by symptoms alone. A patient can feel well while glaucoma continues to progress, so regular reviews remain part of treatment.
A clinician also looks for technique-related problems before changing the medicine. A contaminated nozzle, drops landing on the eyelid instead of the eye, or inconsistent timing can make treatment appear less successful.
A 2023 review in glaucoma care supports individualised pressure targets and continued monitoring rather than relying on a single reading [3].
Bimat treatment for glaucoma or ocular hypertension may continue for months or years when pressure control remains necessary. The duration is determined by the prescribing ophthalmologist, who reviews intraocular pressure, optic-nerve status and visual fields. NICE guidance published in 2022 supports ongoing monitoring for people receiving glaucoma treatment. Long-term use is acceptable when the benefit remains greater than the local adverse effects and follow-up findings support continuation.
Older adults can use bimatoprost when the ophthalmologist considers it suitable, and glaucoma treatment commonly involves long-term pressure monitoring in later life. Age alone does not determine the dose, but other eye diseases, cataract surgery, dry eye and multiple medicines can affect tolerability. The HPRA product information, reviewed in 2024, advises attention to product-specific warnings and adverse reactions in medicine users of all ages. Older patients should also allow time for temporary blurred vision to clear before walking outdoors or driving.
A confirmed allergy or hypersensitivity to bimatoprost or an ingredient in the solution rules out its use. A previous severe eye reaction after a related ophthalmic medicine also requires assessment before treatment is considered. The FDA's 2017 prescribing information identifies hypersensitivity as a contraindication for bimatoprost ophthalmic solution. Severe pain, sudden vision loss or marked swelling after application requires urgent medical attention rather than another dose.
Store Bimat under the temperature and light conditions stated for the product, and protect the bottle from heat, freezing and direct sunlight. During travel, keep it in a stable, protected place rather than a parked car or checked luggage exposed to temperature extremes. WHO medicine-storage principles published in 2020 emphasise protecting medicines from unsuitable heat, moisture and light. Keep the bottle closed and upright when practical, and do not pour it into an unmarked container.
A single ophthalmic application can influence intraocular pressure over the following day, which is why bimatoprost regimens are commonly scheduled once daily when prescribed that way. The duration varies with the person’s eye pressure, drainage pathways and other treatment. The EMA product information for bimatoprost, accessed in 2024, describes pressure-lowering activity extending through the dosing interval. A drop that produces no noticeable sensation may still be working, so symptoms are not a reliable guide to whether another dose is needed.
Diet and exercise do not replace Bimat or directly reproduce its pressure-lowering mechanism. Regular physical activity may support general health, while smoking and uncontrolled cardiovascular risk can worsen broader eye-health risks. The WHO’s 2023 eye-care framework supports management of chronic eye disease through continuing treatment and follow-up. The habits most likely to hinder Bimat are missed doses, poor drop technique, bottle-tip contamination and adding another eye medicine without a treatment plan.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Bimat is provided as sterile eye drops in a 3 ml bottle. The product should be handled as an ophthalmic preparation, with the nozzle kept clean and protected from contact with surrounding surfaces.
Store the bottle according to the product’s labelled storage conditions. Avoid leaving it in direct sunlight, near a radiator or in a hot vehicle. During travel, keep it protected from excessive heat and freezing conditions.
Do not transfer the liquid into another container. A different container may not preserve sterility and can make the product difficult to identify.
If the solution changes appearance, the bottle becomes damaged or the nozzle contacts an unclean surface, stop using it until the situation has been assessed by the dispensing pharmacist or prescribing clinician.
Based on 3 reviews
Used Bimat once daily for glaucoma. The first week brought mild redness and a gritty feeling, but the irritation settled. He found it easier to remember the drop when he used it after brushing his teeth in the evening.
The first week 4 Nov 2026After several weeks, his eye-pressure readings improved at review. He disliked temporary blur after application and waited before driving. Missing doses during a weekend away caused confusion, so he began keeping the bottle with his regular medicines.
Several weeks 7 Oct 2026Used bimatoprost under clinical direction for an eyelash concern rather than glaucoma. He noticed fuller lashes after several weeks, though one side looked slightly longer. Mild eyelid darkening made him reconsider continuing the cosmetic regimen.
Several weeks 24 Oct 2026
